The CRISPR Screen LabTech platform was established to offer a scientific expertise and provide access to a state-of-the-art functional genomic screening platform using CRISPR-Cas9 and support local, regional and national CRISPR screening. We help researchers in screen design, and provide operational support to run the assay and data analysis. We support projects that extend beyond the field of oncology, in immune cell biology, infectiology, neuroimmunology and immunotherapy.
In 2023, the platform was awarded the 3-year "Plateforme Aix-Marseille" label by AMU, INSERM and CNRS. CRISPR screens have become a vital method for the unbiased discovery of genes that, when inactivated, confer sensitivity or resistance to a biological challenge, such as a drug or viral infection. The Platform offers expertise and support in the design and implementation of high-throughput screens, the analysis of genetic modifications on the biological phenotypes of interest (especially survival/proliferation), the monitoring of the screening process, the production of sequencing libraries and the bioinformatics analysis. The currently proposed methods include genome-wide LOF (inactivation, CRISPRko; interference CRISPRi) screens mainly in vitro on human cell lines (+/- co-culture with primary immune cells) and CRISPR screens combined with single cell, and support for validation of candidate genes derived from the screens. Biologist and bioinformatician experts from the Marseille LabTech and the CRISPR platform at UCA will be here to discuss our activities and how we can help launching your projects.
SELECTED PUBLICATIONS:
An OMA1 redox site controls mitochondrial homeostasis, sarcoma growth, and immunogenicity. Miallot R, Millet V, Groult Y, Modelska A, Crescence L, Roulland S, Henri S, Malissen B, Brouilly N, Panicot-Dubois L, Vincentelli R, Sulzenbacher G, Finetti P, Dutour A, Blay JY, Bertucci F, Galland F, Naquet P. Life SciAlliance. 2023 Apr 5;6(6):e202201767
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Shaffer AL 3rd, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, Zhao H, Yu X, Xu W, Roulland S, Ceribelli M, Zhang X, Wilson KM, Chen L, McKnight C, Klumpp-Thomas C, Thomas CJ, Haupl B, Oellerich T, Rae Z, Kelly MC, Ahn IE, Sun C, Gaglione EM, Wilson WH, Wiestner A, Staudt LM. Blood Cancer Discov.2021 Sep 14;2(6):630-647
Inhibition of mitochondrial translation suppresses glioblastoma stem cell growth. Sighel D, Notarangelo M, Aibara S, Re A, Ricci G, Guida M, Soldano A, Adami V, Ambrosini C, Broso F, Rosatti EF, Longhi S, Buccarelli M, D'Alessandris QG, Giannetti S, Pacioni S, Ricci-Vitiani L, Rorbach J, Pallini R, Roulland S, Amunts A, Mancini I, Modelska A*, Quattrone A*. Cell Rep. 2021 Apr 27;35(4):109024
Protocols for CRISPR-Cas9 Screening in Lymphoma Cell Lines. Webster DE, Roulland S, Phelan JD. Methods Mol Biol. 2019 1956:337-350.
A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Phelan JD*, Young RM*, Webster DE*, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM. Nature. 2018 560:387-391
